Applied Genetic Technologies Corporation (NASDAQ:AGTC) will issue its quarterly earnings data after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last posted its quarterly earnings data on Wednesday, September 13th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of $0.22 by ($0.40). Applied Genetic Technologies Corporation had a net margin of 4.28% and a return on equity of 1.45%. The company had revenue of $8.30 million for the quarter, compared to analyst estimates of $12.39 million. During the same quarter in the prior year, the business earned $0.15 EPS. Applied Genetic Technologies Corporation’s revenue was down 31.4% compared to the same quarter last year. On average, analysts expect Applied Genetic Technologies Corporation to post $-0.81 EPS for the current fiscal year and $-1.57 EPS for the next fiscal year.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) traded up 2.94% on Wednesday, hitting $3.50. 16,681 shares of the company were exchanged. The stock has a 50 day moving average price of $3.86 and a 200 day moving average price of $4.82. The firm has a market cap of $63.30 million, a price-to-earnings ratio of 175.00 and a beta of 1.63. Applied Genetic Technologies Corporation has a one year low of $3.40 and a one year high of $10.85.

A number of equities analysts have recently issued reports on the stock. HC Wainwright set a $16.00 target price on shares of Applied Genetic Technologies Corporation and gave the stock a “buy” rating in a research report on Thursday, August 10th. Zacks Investment Research upgraded shares of Applied Genetic Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Cantor Fitzgerald reduced their target price on shares of Applied Genetic Technologies Corporation from $15.00 to $9.00 and set a “neutral” rating on the stock in a research report on Thursday, September 14th. Stifel Nicolaus cut their price objective on shares of Applied Genetic Technologies Corporation from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, September 14th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $7.00 price objective (down from $14.00) on shares of Applied Genetic Technologies Corporation in a report on Thursday, September 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $11.71.

COPYRIGHT VIOLATION WARNING: “Applied Genetic Technologies Corporation (AGTC) Set to Announce Quarterly Earnings on Tuesday” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/01/applied-genetic-technologies-corporation-agtc-set-to-announce-quarterly-earnings-on-tuesday.html.

About Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Earnings History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.